Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Moderate Buy” by Analysts

Posted by on May 18th, 2026

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL – Get Free Report) have been given an average recommendation of “Moderate Buy” by the nine analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and two have issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $8.75.

A number of analysts recently commented on AUTL shares. HC Wainwright boosted their target price on shares of Autolus Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 9th. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Friday, March 13th. Finally, Mizuho dropped their target price on shares of Autolus Therapeutics from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday, March 31st.

Read Our Latest Research Report on AUTL

Institutional Investors Weigh In On Autolus Therapeutics

A number of large investors have recently made changes to their positions in the company. Mak Capital One LLC raised its holdings in shares of Autolus Therapeutics by 15.3% during the fourth quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after acquiring an additional 3,987,727 shares during the period. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 12.2% during the fourth quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after acquiring an additional 1,900,000 shares during the period. Schroder Investment Management Group raised its holdings in shares of Autolus Therapeutics by 12.5% during the fourth quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after acquiring an additional 1,056,092 shares during the period. Bank of America Corp DE raised its holdings in shares of Autolus Therapeutics by 108.1% during the third quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after acquiring an additional 1,054,458 shares during the period. Finally, Atle Fund Management AB raised its holdings in shares of Autolus Therapeutics by 5.8% during the third quarter. Atle Fund Management AB now owns 1,169,634 shares of the company’s stock valued at $1,907,000 after acquiring an additional 64,173 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Price Performance

NASDAQ AUTL opened at $1.63 on Monday. The company’s 50 day simple moving average is $1.48 and its 200 day simple moving average is $1.51. Autolus Therapeutics has a 12 month low of $1.18 and a 12 month high of $2.70. The company has a market capitalization of $433.81 million, a P/E ratio of -1.50 and a beta of 1.93.

Autolus Therapeutics (NASDAQ:AUTL – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 128.59%. The business had revenue of $26.22 million for the quarter, compared to the consensus estimate of $26.27 million. On average, analysts anticipate that Autolus Therapeutics will post -1.04 earnings per share for the current year.

About Autolus Therapeutics

(Get Free Report)

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.

Featured Stories

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.